199 related articles for article (PubMed ID: 23912642)
1. Serum galectin-3 level in systemic sclerosis.
Koca SS; Akbas F; Ozgen M; Yolbas S; Ilhan N; Gundogdu B; Isik A
Clin Rheumatol; 2014 Feb; 33(2):215-20. PubMed ID: 23912642
[TBL] [Abstract][Full Text] [Related]
2. The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients.
Shi Z; Meng Z; Han Y; Cao C; Tan G; Wang L
Lupus; 2018 Apr; 27(4):621-627. PubMed ID: 29058991
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
[TBL] [Abstract][Full Text] [Related]
4. Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis.
Stochmal A; Czuwara J; Zaremba M; Rudnicka L
Arch Dermatol Res; 2020 Aug; 312(6):453-458. PubMed ID: 31667578
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
6. Serum osteopontin and vitronectin levels in systemic sclerosis.
Gundogdu B; Yolbas S; Yilmaz M; Aydin S; Koca SS
Adv Clin Exp Med; 2017 Nov; 26(8):1231-1236. PubMed ID: 29264880
[TBL] [Abstract][Full Text] [Related]
7. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus.
Matsuoka N; Fujita Y; Temmoku J; Furuya MY; Asano T; Sato S; Matsumoto H; Kobayashi H; Watanabe H; Suzuki E; Kozuru H; Yastuhashi H; Migita K
PLoS One; 2020; 15(1):e0227069. PubMed ID: 31986153
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 is an independent predictor of survival in systemic sclerosis.
Faludi R; Nagy G; Tőkés-Füzesi M; Kovács K; Czirják L; Komócsi A
Int J Cardiol; 2017 Apr; 233():118-124. PubMed ID: 28043664
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis.
Gigante A; Iannazzo F; Navarini L; Sgariglia MC; Margiotta DPE; Vaiarello V; Foti F; Afeltra A; Cianci R; Rosato E
Clin Rheumatol; 2021 Oct; 40(10):4253-4258. PubMed ID: 33839992
[TBL] [Abstract][Full Text] [Related]
10. [THE ROLE OF SEMAPHORIN 7A IN SYSTEMIC SCLEROSIS].
Rimar D; Slobodin G; Rosner I; Rozenbaum M; Kaly L; Boulman N; Jiries N; Awisat A; Vadasz Z
Harefuah; 2017 Jul; 156(7):418-421. PubMed ID: 28786275
[TBL] [Abstract][Full Text] [Related]
11. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity.
Lee YJ; Kang SW; Song JK; Park JJ; Bae YD; Lee EY; Lee EB; Song YW
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S41-5. PubMed ID: 17949550
[TBL] [Abstract][Full Text] [Related]
12. The circulating cell-free microRNA profile in systemic sclerosis is distinct from both healthy controls and systemic lupus erythematosus.
Steen SO; Iversen LV; Carlsen AL; Burton M; Nielsen CT; Jacobsen S; Heegaard NH
J Rheumatol; 2015 Feb; 42(2):214-21. PubMed ID: 25399392
[TBL] [Abstract][Full Text] [Related]
13. Plasma galectin-3 levels do not differ in systemic lupus erythematosus patients.
Zhao CN; Mao YM; Liu LN; Wu Q; Dan YL; Pan HF
Int J Rheum Dis; 2019 Oct; 22(10):1820-1824. PubMed ID: 31402566
[TBL] [Abstract][Full Text] [Related]
14. Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.
Carlsson A; Wuttge DM; Ingvarsson J; Bengtsson AA; Sturfelt G; Borrebaeck CA; Wingren C
Mol Cell Proteomics; 2011 May; 10(5):M110.005033. PubMed ID: 21350050
[TBL] [Abstract][Full Text] [Related]
15. Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy.
Yanaba K; Asano Y; Akamata K; Noda S; Aozasa N; Taniguchi T; Takahashi T; Toyama T; Ichimura Y; Sumida H; Kuwano Y; Miyazaki M; Sato S
Int J Rheum Dis; 2016 Jun; 19(6):622-7. PubMed ID: 24517166
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
Sato S; Nagaoka T; Hasegawa M; Tamatani T; Nakanishi T; Takigawa M; Takehara K
J Rheumatol; 2000 Jan; 27(1):149-54. PubMed ID: 10648031
[TBL] [Abstract][Full Text] [Related]
17. Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus.
Shi ZR; Tan GZ; Meng Z; Yu M; Li KW; Yin J; Wei KH; Luo YJ; Jia SQ; Zhang SJ; Wu J; Mi XB; Wang L
Arthritis Rheumatol; 2015 Jan; 67(1):193-203. PubMed ID: 25307291
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders.
Stuart RA; Littlewood AJ; Maddison PJ; Hall ND
Clin Exp Rheumatol; 1995; 13(1):17-22. PubMed ID: 7774098
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants in
Cunha EGC; de Lima CAD; Vilar KM; Nóbrega MF; Almeida AR; Pereira MC; Dantas AT; Gonçalves RSG; Rêgo MJBM; Duarte ALBP; Pitta MGDR
Autoimmunity; 2021 Jun; 54(4):187-194. PubMed ID: 33973825
[TBL] [Abstract][Full Text] [Related]
20. Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients - Relationship with biochemical and echocardiography parameters.
Hromádka M; Seidlerová J; Suchý D; Rajdl D; Lhotský J; Ludvík J; Rokyta R; Baxa J
Int J Cardiol; 2017 Dec; 249():448-453. PubMed ID: 28935460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
